The primary objective of this study is to assess adherence and persistence to BETASERON therapy in patients who are using the BETACONNECT auto-injector device (BETACONNECT device). The secondary objective of this study is to assess patient-reported satisfaction with the BETACONNECT device.
Study Type
OBSERVATIONAL
Enrollment
146
Applied via the BETACONNECT device. Dose as prescribed by physician.
Used to apply Betaseron.
Unnamed facility
Cullman, Alabama, United States
Unnamed facility
Boca Raton, Florida, United States
Number of BETASERON injections as captured by the BETACONNECT device
Time frame: At 6 months
Time (days) between BETASERON injections as captured by BETACONNECT device
Time frame: At 6 months
Patient reported satisfaction by a questionnaire
Time frame: At 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
New Port Richey, Florida, United States
Unnamed facility
Tampa, Florida, United States
Unnamed facility
Atlanta, Georgia, United States
Unnamed facility
Fulton, Maryland, United States
Unnamed facility
Foxborough, Massachusetts, United States
Unnamed facility
Deckerville, Michigan, United States
Unnamed facility
St Louis, Missouri, United States
Unnamed facility
Stratford, New Jersey, United States
...and 13 more locations